Mostrar el registro sencillo del ítem
dc.contributor.author
Allegri, Ricardo Francisco
dc.contributor.author
Guekht, A.
dc.date.available
2023-05-04T20:13:56Z
dc.date.issued
2012-04
dc.identifier.citation
Allegri, Ricardo Francisco; Guekht, A.; Cerebrolysin improves symptoms and delays progression in patients with alzheimer's disease and vascular dementia; Prous Science; Drugs Of Today; 48; SUPPL. A; 4-2012; 25-41
dc.identifier.issn
1699-3993
dc.identifier.uri
http://hdl.handle.net/11336/196369
dc.description.abstract
Dementia is the result of various cerebral disorders, leading to an acquired loss of memory and impaired cognitive ability. The most common forms are Alzheimer´s disease(AD) and vascular dementia (VaD). Neurotrophic factors are essential for the survival and differentiation of developing neurons and protecting them against damage under pathologic conditions. Cerebrolysin is a peptide preparation that mimics the pleiotropic effects of neurotrophic factors Several clinical trials investigating the therapeutic efficacy of Cerebrolysin in AD and VaD have confirmed the proof of concept. The results of these trials have shown statistically significant and clinically relevant treatment effects of Cerebrolysin on cognitive, global and functional domains in mild to moderately severe stages of dementia. Doses of 10 and 30 mL were the most effective, but higher doses of up to 60 mL turned out to be most effective in improving neuropsychiatric symptoms, which become relevant at later stages of the disease. Combining treatment with cholinesterase inhibitors and Cerebrolysin indicated long-term synergistic treatment effects in mild to moderate AD. The efficacy of Cerebrolysin persisted for up to several months after treatment suggesting Cerebrolysin has not merely symptomatic benefits, but a disease-delaying potential. This paper reviews the clinical efficacy of Cerebrolysin in the treatment of dementia. Data were obtained from international, multicenter, randomized clinical trials performed in compliance with Good Clinical Practice and the principles of the Declaration of Helsinki (1964) and subsequent revisions.
dc.format
application/pdf
dc.language.iso
eng
dc.publisher
Prous Science
dc.rights
info:eu-repo/semantics/openAccess
dc.rights.uri
https://creativecommons.org/licenses/by-nc-sa/2.5/ar/
dc.subject
Cerebrolysin
dc.subject
Alzheimer
dc.subject
Dementia
dc.subject
Vascular
dc.subject.classification
Neurología Clínica
dc.subject.classification
Medicina Clínica
dc.subject.classification
CIENCIAS MÉDICAS Y DE LA SALUD
dc.title
Cerebrolysin improves symptoms and delays progression in patients with alzheimer's disease and vascular dementia
dc.type
info:eu-repo/semantics/article
dc.type
info:ar-repo/semantics/artículo
dc.type
info:eu-repo/semantics/publishedVersion
dc.date.updated
2023-04-26T10:46:14Z
dc.journal.volume
48
dc.journal.number
SUPPL. A
dc.journal.pagination
25-41
dc.journal.pais
España
dc.description.fil
Fil: Allegri, Ricardo Francisco. Fundación para la Lucha Contra las Enfermedades Neurológicas de la Infancia. Instituto de Investigaciones Neurológicas "Raúl Carrea"; Argentina
dc.description.fil
Fil: Guekht, A.. Russian National Research Medical University; Rusia
dc.journal.title
Drugs Of Today
dc.relation.alternativeid
info:eu-repo/semantics/altIdentifier/doi/http://dx.doi.org/10.1358/dot.2012.48(Suppl.A).1739721
Archivos asociados